CD274 and myocarditis: Cathcart-Rake (2020) evaluated irAEs incidence in patients with NSCLC who received PD-1 or PD-L1 inhibitors using a US commercial insurance database and found the rate of myocarditis to be 0.89% by month 9 after ICI initiation [22].